Cite Filings / SABS / 0001346824-26-000079
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13D/A

Beneficial Ownership Report

SAB Biotherapeutics, Inc. · Filed 2026-03-23 · Acc 0001346824-26-000079

Documents 1

  • SCHEDULE 13D/A Beneficial Ownership Report , xslSCHEDULE_13D_X02/primary_doc.xml

Around this filing

  • 2026-08-10 SCHEDULE 13D/A Beneficial Ownership Report
  • 2026-03-25 4 CHIEF MEDICAL OFFICER gave up 988 shares (to pay taxes)
  • 2026-03-23 SCHEDULE 13D/A Beneficial Ownership Report
  • 2026-03-19 8-K Material agreement · Other events
  • 2026-03-19 424B5 Prospectus
  • 2026-03-17 424B5 Prospectus
  • 2026-03-11 SCHEDULE 13D/A Beneficial Ownership Report

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · Vivo Opportunity Fund Holdings, L.P. 9.99%
  2. 2026-11-16 SCHEDULE 13G/A · BALYASNY ASSET MANAGEMENT L.P. 7.94%
  3. 2026-11-16 SCHEDULE 13G/A · Woodline Partners LP 5.7%
Loading xslSCHEDULE_13D_X02/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…